Icon PLC (NASDAQ:ICLR)‘s stock had its “buy” rating restated by investment analysts at KeyCorp in a research report issued to clients and investors on Wednesday. They presently have a $85.00 price objective on the stock. KeyCorp’s price target indicates a potential upside of 14.00% from the company’s current price.
Other hedge funds recently modified their holdings of the company. Foresters Investment Management Company Inc. boosted its stake in shares of Icon PLC by 1.0% in the fourth quarter. Foresters Investment Management Company Inc. now owns 99,000 shares of the company’s stock worth $7,692,000 after buying an additional 1,000 shares during the last quarter. WCM Investment Management CA boosted its stake in shares of Icon PLC by 7.1% in the fourth quarter. WCM Investment Management CA now owns 4,490,038 shares of the company’s stock worth $348,876,000 after buying an additional 297,587 shares during the last quarter. Globeflex Capital L P boosted its stake in shares of Icon PLC by 10.4% in the fourth quarter. Globeflex Capital L P now owns 268,600 shares of the company’s stock worth $20,870,000 after buying an additional 25,200 shares during the last quarter. Financial Counselors Inc. boosted its stake in shares of Icon PLC by 2.6% in the fourth quarter. Financial Counselors Inc. now owns 29,978 shares of the company’s stock worth $2,329,000 after buying an additional 753 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Icon PLC by 6.2% in the fourth quarter. Ameriprise Financial Inc. now owns 147,147 shares of the company’s stock worth $11,433,000 after buying an additional 8,529 shares during the last quarter.
Shares of Icon PLC (NASDAQ:ICLR) traded up 4.47% during mid-day trading on Wednesday, hitting $77.89. The stock had a trading volume of 831,504 shares. Icon PLC has a 12 month low of $62.31 and a 12 month high of $84.14. The stock’s 50-day moving average is $69.29 and its 200 day moving average is $69.50. The company has a market cap of $4.29 billion and a PE ratio of 18.59.
A number of other research analysts also recently issued reports on ICLR. Zacks Investment Research downgraded Icon PLC from a “buy” rating to a “hold” rating in a report on Wednesday, April 27th. SunTrust Banks Inc. reissued a “buy” rating on shares of Icon PLC in a report on Wednesday, April 27th. Jefferies Group reissued a “buy” rating and issued a $80.00 target price (down previously from $85.00) on shares of Icon PLC in a report on Thursday, April 28th. Avondale Partners downgraded Icon PLC from a “market perform” rating to an “underperform” rating and lowered their target price for the company from $70.00 to $59.00 in a report on Wednesday, June 8th. Finally, Credit Suisse Group AG assumed coverage on Icon PLC in a report on Monday, June 20th. They issued an “outperform” rating and a $80.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Icon PLC currently has an average rating of “Hold” and a consensus price target of $78.19.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
